CAR-T therapy, or chimeric antigen receptor T-cell therapy, has emerged as one of the most potent weapons against relapsed or refractory multiple myeloma, a cancer characterized by the malignant proliferation of plasma cells within bone marrow. By genetically reprogramming a patient’s own T cells to recognize and obliterate cancerous cells, CAR-T therapy has achieved remarkable remission rates where conventional treatments often fail. However, the therapy is double-edged, as it can trigger CRS—an excessive immune response marked by the release of cytokines, leading to symptoms ranging from fever and hypotension to respiratory distress and multi-organ failure.

CRS represents a daunting hurdle in the clinical application of CAR-T treatments. Its unpredictable onset and rapid progression necessitate close hospital monitoring, often restricting therapy to inpatient settings and imposing significant burdens on patients and healthcare systems alike. Traditionally, CRS detection relies on intermittent nursing assessments and laboratory analyses, which might miss subtle early signs that herald the escalation of inflammation. To address this gap, the multidisciplinary team at Mount Sinai explored the utility of continuous physiological data collection through wearable sensors as a noninvasive, real-time surveillance method to identify the earliest manifestations of CRS.

The pilot study enrolled 30 individuals with multiple myeloma who were undergoing CAR-T therapy at The Mount Sinai Hospital. Each participant was equipped with a wearable device designed to monitor multiple vital parameters, including skin and axillary temperature, heart rate, blood oxygen saturation, respiratory rate, and physical activity. In parallel, blood samples were periodically collected to quantify circulating cytokine levels, shedding light on the molecular underpinnings of CRS pathogenesis. This integrative approach allowed the team to correlate fluctuations in wearable-derived data with biological markers of inflammation.

Among 25 patients whose data were fully analyzable, the wearable devices detected 18 out of 20 clinically diagnosed CRS episodes, identifying alarming physiological changes a median of seven hours before they were recognized by standard nursing evaluations. This temporal lead time is critically important as it could enable preemptive clinical interventions to mitigate severe complications. The continuous temperature measurements from the skin and underarm, in particular, emerged as a sensitive early indicator closely mirroring the changes in interferon gamma (IFN-γ), a key inflammatory cytokine implicated in CRS.

The correlation between wearable data and cytokine profiles not only validates the physiological signals captured by the devices but also promises to enhance predictive algorithms for CRS onset. Dr. Samir Parekh, senior corresponding author and Professor of Medicine at Mount Sinai, emphasized that while these findings are preliminary, they highlight the transformative potential of integrating wearable technology into cancer immunotherapy protocols. If these results are replicated in larger cohorts, wearable monitoring could facilitate safer administration of CAR-T outside hospitals, broadening patient access and alleviating the strain on medical facilities.

Another critical aspect underscored by the research is the patient-centric benefit of remote continuous monitoring. Early detection of CRS through wearables could minimize the severity of symptoms, reduce intensive care admissions, and improve overall patient comfort and quality of life by enabling timely outpatient interventions. Dr. Adriana Rossi, co-corresponding author, noted that the real-time insights afforded by wearable sensors equip clinicians with a dynamic view of immune system activity and enable a more precise and proactive therapeutic approach.

Furthermore, the integration of biologic markers such as cytokine profiling with wearable-derived physiological signals signifies a new frontier in personalized oncology care. Dr. Alessandro Laganà, a co-corresponding author and assistant professor specializing in genetics and genomic sciences, remarked that this multimodal monitoring approach could pave the way for “smarter” health technologies. These systems could eventually predict patient-specific toxicity risks, tailor therapeutic regimens, and ultimately optimize clinical outcomes in the era of precision medicine.

Despite these promising findings, the researchers caution against overinterpretation due to the study’s limitations, including its small sample size and single-center design. They advocate for extensive multicenter trials to validate the reliability, scalability, and cost-effectiveness of wearable monitoring in diverse patient populations and in outpatient care settings where early identification and management of CRS could vastly improve treatment safety.

This innovative research was generously supported by Bristol Myers Squibb and the Center of Excellence for Multiple Myeloma Philanthropic Fund, along with significant grants from the National Cancer Institute and the American Society of Hematology. The collaboration exemplifies the growing convergence between oncology, technology, and immunology—fields that, when integrated thoughtfully, hold the promise of reshaping cancer treatment paradigms.

As CAR-T therapies continue to expand their reach beyond hematologic malignancies into solid tumors and other refractory cancers, the ability to monitor and mitigate adverse immune effects swiftly will be paramount. Wearable technologies represent a compelling step toward real-time, personalized monitoring that can make these cutting-edge therapies more accessible and safer. This breakthrough also underscores the potential for digital health innovations to transform patient monitoring, offering hope for improved survival and enhanced quality of life among those battling cancer.

The convergence of continuous physiological monitoring with cytokine analysis thus emerges as a powerful tool to illuminate the complex immune landscapes in CAR-T therapy recipients. Moving forward, harnessing this synergy may unlock novel predictive models and intervention strategies, alleviating one of the most challenging barriers to the broader dissemination of life-saving immunotherapies. This seminal work lays the foundation for a new era of cancer care where wearable devices are integral to treatment precision and patient safety.

Subject of Research: People

Article Title: Detection of cytokine release syndrome using wearables and cytokine profiling following CAR-T therapy for myeloma

News Publication Date: 22-Jun-2026

Web References: doi.org/10.1172/jci.insight.203988

Keywords: Cytokine storm, Multiple myeloma, CAR-T therapy, Cytokine release syndrome, Wearable technology, Immunotherapy toxicity, Interferon gamma, Continuous monitoring, Cancer immunotherapy, Personalized medicine

Conventional T cells, while highly potent effector cells in immune surveillance and destruction of malignant cells, exhibit inherent functional constraints that impact CAR-T therapy outcomes. Factors such as exhaustion after repeated antigen stimulation, limited persistence, and the immunosuppressive tumor microenvironment dampen their sustained anti-tumor activity. Moreover, limitations in trafficking to tumor sites, issues with cytokine release syndrome, and the risk of graft-versus-host disease in allogeneic CAR-T treatments add further complexity. The manufacturing process itself, which typically involves autologous T cell collection, genetic modification, and expansion, is time-consuming, costly, and often results in products with variable quality and efficacy.

In response to these challenges, scientific efforts have increasingly turned towards harnessing the unique properties of immune cells beyond conventional αβ T cells. This strategy, broadly designated as “CAR-X” cell engineering, leverages the diverse biology of alternative immune populations such as natural killer (NK) cells, invariant natural killer T (iNKT) cells, γδ T cells, and macrophages. Each of these cell types possesses distinct functional attributes that may complement or surpass the capabilities of traditional CAR-T cells. Consequently, CAR-X therapies promise to enhance clinical efficacy, reduce side effects, and enable applications across a broader spectrum of diseases including solid tumors, infectious diseases, and autoimmune disorders.

Natural killer cells, for instance, play a vital role in innate immunity through their ability to recognize and eliminate virally infected or transformed cells without prior sensitization. Their intrinsic cytotoxicity and cytokine secretion profiles endow them with rapid effector functions. Notably, NK cells display a reduced risk of causing graft-versus-host disease, making them attractive candidates for allogeneic “off-the-shelf” CAR therapies. However, the limited in vivo persistence and challenges in genetic modification have historically hindered their development. Advances in gene editing and culture conditions are addressing these issues, enabling the generation of CAR-NK products with improved longevity and potent tumor-killing capacities.

Invariant natural killer T cells combine features of both innate and adaptive immunity with their semi-invariant T cell receptors recognizing glycolipid antigens presented by CD1d molecules. This unique biology allows iNKT cells to modulate the immune microenvironment profoundly, not only attacking tumor cells directly but also stimulating other immune effectors and overcoming immunosuppression. Engineering CARs into iNKT cells leverages these dual functionalities, offering a multifaceted therapeutic approach. Furthermore, iNKT cells exhibit lower alloreactivity, suggesting a safer profile for allogenic therapies.

Similarly, γδ T cells represent a distinct T cell lineage characterized by their γδ T cell receptors, which recognize stress-induced ligands independent of major histocompatibility complex (MHC) presentation. This property confers several advantages, including broad tumor recognition and the ability to function in an immunosuppressive milieu. CAR-γδ T cells can exploit these features to target cancers resistant to conventional therapies while benefiting from innate-like recognition pathways that limit immune escape. Ongoing innovations in ex vivo expansion and genetic engineering techniques are enabling scalable production of CAR-γδ T cell products.

Macrophages, traditionally viewed as phagocytic cells involved in tissue homeostasis and inflammation, are emerging as compelling vectors for CAR therapy due to their natural tumor infiltration and antigen-presenting capabilities. CAR-macrophages can potentially engulf and destroy tumor cells directly and orchestrate robust antitumor immune responses by activating adaptive immunity. Moreover, they can be engineered to remodel the tumor microenvironment, counteracting immune evasion mechanisms. Despite technical challenges in genetic modification and expansion, recent breakthroughs in viral and non-viral transduction methodologies have propelled CAR-macrophage development forward.

The design of CAR constructs tailored specifically to each immune cell type is another critical frontier in CAR-X engineering. Conventional CARs optimized for αβ T cells may not fully harness the unique signaling pathways and functional mechanisms of alternative immune cells. For example, CARs in NK cells often incorporate signaling domains derived from activating NK receptors like NKG2D or DAP12 to promote-specific activation, while CARs for macrophages integrate phagocytosis-inducing domains. Fine-tuning CAR architecture to synergize with endogenous signaling can substantially enhance efficacy and persistence within the host.

Manufacturing platforms are also evolving to accommodate the cell-specific requirements of CAR-X therapies. Whereas CAR-T cell production typically relies on lentiviral or retroviral transduction of T cells collected via leukapheresis, alternative approaches such as non-viral gene editing, mRNA electroporation, and stem cell differentiation protocols are being adapted. These tailored manufacturing strategies aim to improve scalability, safety profiles, and the timely generation of clinical-grade CAR-X products. Additionally, the potential to create universal donor cell banks using gene editing to prevent rejection or graft-versus-host disease presents a paradigm shift toward ready-to-use allogeneic cell therapies.

From a clinical perspective, early-phase trials integrating CAR-NK, CAR-iNKT, and CAR-γδ T cells have demonstrated encouraging safety profiles and preliminary efficacy signals, particularly in refractory hematological malignancies. The intrinsic biology of these cells contributes to attenuated cytokine release syndromes and neurotoxicity, which are common adverse events in CAR-T therapy. Moreover, solid tumor targeting, a notorious hurdle for CAR-T cells, may be more achievable with CAR-X cells due to their distinct trafficking and tissue-infiltrating capabilities. Accordingly, the clinical landscape is rapidly expanding, encompassing hematologic cancers, solid malignancies, viral infections, and even fibrotic or autoimmune diseases.

Despite these exciting developments, significant challenges remain in translating CAR-X technologies into widely available therapies. The heterogeneity of alternative immune cells necessitates optimization in expansion, persistence, and potency to achieve consistent therapeutic responses. Immune evasion by tumors, antigen heterogeneity, and immune suppression continue to pose obstacles that demand combinatorial or multifunctional engineering strategies. Concurrently, regulatory frameworks must adapt to the complexity of these novel therapies to ensure safety without stifling innovation.

In summary, CAR-X cell engineering represents a transformative frontier in immunotherapy, leveraging the diversity of the immune system to overcome the constraints of conventional CAR-T approaches. By harnessing the unique effector mechanisms and biological properties of NK cells, iNKT cells, γδ T cells, macrophages, and potentially other immune subsets, this paradigm expansion is poised to unlock new avenues for treating cancer and beyond. The iterative refinement of cell-specific CAR designs, manufacturing methods, and clinical applications heralds a future where personalized, effective, and safer cellular therapies redefine medicine.

As research accelerates, collaborations between academic institutions, biotechnology companies, and regulatory agencies will be paramount in propelling CAR-X therapies from experimental stages to mainstream clinical use. Integrative efforts that combine multi-omic profiling, machine learning, and synthetic biology will undoubtedly yield next-generation CAR constructs and cell products with enhanced functionality. In concert, ongoing clinical trials will illuminate the therapeutic landscape, refining indications, dosing regimens, and combination approaches to optimize patient outcomes.

Ultimately, the story of CAR-X cell engineering is one of innovation driven by the limitations of prior successes, a testament to the relentless pursuit of harnessing the immune system’s vast potential. The next decade promises to be pivotal, with the envisioned convergence of diverse immune cell engineering shaping a new chapter in immunotherapy that extends hope to millions of patients worldwide.

Subject of Research: Development and application of alternative immune cells engineered with chimeric antigen receptors (CAR-X) for enhanced immunotherapy.

Article Title: CAR-X cell engineering.

Article References:
Li, X., Lin, H., Liang, J. et al. CAR-X cell engineering. Nat Rev Bioeng (2026). https://doi.org/10.1038/s44222-026-00430-w